Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

CJC-1295 and ipamorelin: what is in it and does it work?

CJC-1295 and ipamorelin pair a GHRH analog with a ghrelin mimetic to raise growth hormone. The pair is untested, and neither peptide has a lawful path.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

At a glance

CJC-1295 and ipamorelin is a popular pairing of a long-acting GHRH analog with a selective ghrelin receptor agonist, sold premixed or as two vials to raise growth hormone. No study has tested the combination: CJC-1295 has small hormone trials, and ipamorelin has one small growth hormone pharmacology study in healthy men, while its only randomized trial was negative for a surgical use. Neither peptide can be lawfully compounded in the United States.

Evidence: Blend never studiedRegulatory: No federal basis to compoundWADA: WADA prohibited
What is in it
CJC-1295, Ipamorelin
Evidence for the combination
No published study of the blend. Each ingredient is graded on its own.
Legal status
No federal basis to compound, set by CJC-1295 and Ipamorelin.
Tested athletes
Prohibited: CJC-1295 and Ipamorelin are on the WADA list.

What is in the CJC-1295 and ipamorelin blend?

CJC-1295 and ipamorelin contains CJC-1295 and Ipamorelin. Most products sold under this name pair ipamorelin with modified GRF (1-29), usually labeled CJC-1295 without DAC, rather than the long-acting CJC-1295 with DAC that was tested in trials. They are different molecules with very different half-lives. Amounts and ratios vary by seller, and research-chemical labels are not verified. PeptideAgent does not name or link sellers.

Also searched as: CJC-1295 ipamorelin; CJC-1295/ipamorelin blend; CJC ipamorelin; Ipamorelin CJC-1295; Mod GRF 1-29 and ipamorelin.

Ingredients in the CJC-1295 and ipamorelin blend, with each peptide's own evidence grade, FDA status, and WADA status
IngredientWhy it is in the mixStatus (alone)
CJC-1295Sold to stimulate growth hormone release through the GHRH receptor, based on small human trials that measured GH and IGF-1.
Evidence: Human RCT evidence
Regulatory: Nomination withdrawn
WADA: WADA prohibited
IpamorelinSold to trigger growth hormone pulses through the ghrelin receptor, based on animal studies and one small human pharmacology study.
Evidence: Human RCT evidence
Regulatory: Nomination withdrawn
WADA: WADA prohibited

Grades and statuses come from each peptide's own record and update with it. Grades follow the methodology.

Why are these peptides combined in the CJC-1295 and ipamorelin blend?

The pairing rests on real physiology. Growth hormone release is driven by two pathways: GHRH acting on its own receptor, and ghrelin-like signals acting on the growth hormone secretagogue receptor. In a 1990 study of 18 healthy men, a single intravenous dose of GHRH given with a synthetic ghrelin receptor hexapeptide released more growth hormone than either alone, a synergy that suggested the two act independently.

Sellers extend that finding to CJC-1295 and ipamorelin. But the 1990 study used different molecules, single intravenous doses, and a one-hour hormone readout. It says nothing about repeated injections, body composition, or the safety of the pair sold today. [1] [2] [3]

Has the CJC-1295 and ipamorelin blend been studied?

No published study has tested CJC-1295 with ipamorelin in humans or animals, and PubMed indexes no trial of the pair.

CJC-1295 alone has small randomized trials in healthy adults: a single injection raised mean growth hormone 2 to 10 fold for 6 or more days and IGF-1 1.5 to 3 fold for 9 to 11 days. Those trials measured hormones only, not muscle, fat, sleep, or any clinical outcome, and development was discontinued.

Ipamorelin's only randomized human trial gave it intravenously after bowel surgery and found no significant difference from placebo in time to the first tolerated meal. One small human pharmacology study showed a single IV infusion releases growth hormone in healthy men, but no human study reports growth hormone, IGF-1, or body composition with the injections sold today. [1] [3] [6] [14]

What each ingredient has shown alone

  • CJC-1295 (human RCT evidence). Long acting lab-made growth hormone releasing hormone: small randomized trials raised GH 2 to 10 fold and IGF-1 1.5 to 3 fold per dose; no compounding basis.
  • Ipamorelin (human RCT evidence). Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; its one randomized placebo controlled trial, after bowel surgery, found no benefit.

CJC-1295 and ipamorelin results and before and after claims

People searching for CJC-1295 and ipamorelin results often ask how long it takes to see changes in muscle, fat, or sleep. No study has measured those outcomes for the pair or for either peptide alone, so there is no evidence-based timeline.

What has been measured is hormones: CJC-1295 raises growth hormone and IGF-1 in healthy adults. Higher IGF-1 is not the same as more muscle or less fat. The GHRH analog with measured body composition results is tesamorelin, which reduced visceral fat in trials in HIV lipodystrophy, and that result does not transfer to other peptides.

A 2026 review of growth hormone axis peptides used outside medical care describes the uncertainty around product composition, dose, and stacking in unregulated supply, and the resulting uncertainty about claimed body recomposition benefits. Before and after photos cannot resolve it. [3] [4] [8]

What are the side effects of the CJC-1295 and ipamorelin blend?

No study has recorded the side effects of the combination. In CJC-1295 trials the common effects were injection site reactions, flushing, headache, and transient warmth, and FDA cited increased heart rate and a systemic vasodilatory reaction among serious adverse events when it evaluated CJC-1295 for its Category 2 list.

Raising growth hormone through two routes at once could add up effects such as water retention, joint aches, tingling, higher blood glucose, and increased appetite from ghrelin receptor activation. A 2026 review of growth hormone axis peptides lists prolactin and cortisol rises, appetite changes, blood glucose problems, fluid retention, muscle and joint pain, and injection site reactions among reported adverse effects.

FDA also cited immunogenicity risk from aggregation and impurities when it placed ipamorelin on the Category 2 list in 2023. Long-term effects of sustained IGF-1 elevation, including on existing tumors, have not been studied. [3] [8] [10]

Reported for each ingredient

From each peptide's record. These were reported for the peptide alone, not for the blend. Absence of data is not evidence of safety.

Side effects reported for each ingredient of the CJC-1295 and ipamorelin blend
IngredientReported side effects and safety notes
CJC-1295
  • Injection site reactions (most common in trials)
  • Flushing, headache, and transient warmth or vasodilation shortly after injection
  • Increased heart rate and a systemic vasodilatory reaction were among the serious adverse events FDA cited in its Category 2 evaluation
  • Water retention, tingling, and joint aches consistent with raised GH and IGF-1 reported in trials and anecdotally
Ipamorelin
  • No safety signal versus placebo in the 7 day intravenous ileus trial (adverse events 87.5% versus 94.8%, mostly surgical)
  • Injection site reactions, headache, flushing, and lightheadedness reported anecdotally
  • Increased appetite (ghrelin receptor effect) reported anecdotally
  • FDA cited immunogenicity risk from aggregation and impurities and limited safety data by the routes used in compounding when it placed ipamorelin in Category 2
Regulatory: No federal basis to compoundWADA: WADA prohibited

A blend inherits the strictest status among its ingredients, because a mixed product is only as lawful as its least lawful component. For the CJC-1295 and ipamorelin blend that is CJC-1295 and Ipamorelin: no federal basis to compound. At least one ingredient is not FDA approved and not on the 503A bulks list, so a licensed pharmacy has no federal basis to compound the mix.

Why blends like this are sold as research chemicals

A drug for human use in the United States has to be FDA approved or lawfully compounded by a licensed pharmacy for a named patient under a prescription. This blend can be neither, so vials sold under its name carry labels such as “for research use only” or “not for human consumption”. That label does not make a product lawful to inject, and it means no one has checked the vial for identity, purity, sterility, or amount. [11]

WADA status

CJC-1295 and Ipamorelin are prohibited at all times on the WADA list, so any product containing them is prohibited for athletes subject to anti-doping testing.

State rules: peptide laws by state. All FDA actions: regulatory tracker.

What does the CJC-1295 and ipamorelin blend cost, and what can a provider lawfully offer?

Neither peptide has a lawful path. FDA placed CJC-1295 and ipamorelin on the 503A Category 2 list in September 2023; the 503A nominations were later withdrawn, and FDA's April 2026 update lists both as nominated but withdrawn rather than on the bulks list. Neither was reviewed at the July 2026 advisory committee meeting, and neither is a component of an approved drug.

Licensed 503A pharmacies and 503B outsourcing facilities therefore have no federal basis to compound either peptide, alone or combined, and there is no lawful price. Advertised prices come from research-chemical sellers and clinics.

The one GHRH analog in the catalog with FDA approval is tesamorelin (Egrifta), approved to reduce excess abdominal fat in adults with HIV lipodystrophy. It is a different molecule with its own label, and it can be prescribed. [9] [10] [11] [12]

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [16] [17] [18]

Being offered does not change the legal status of the CJC-1295 and ipamorelin blend. CJC-1295 and ipamorelin are not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound the mix. [10] [11]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [10] [16] [19] [20] [21] [22]

What that means for you

  • A pharmacy that compounds the CJC-1295 and ipamorelin blend is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [16] [19]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [22]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [23]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [24] [25]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [10]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, the CJC-1295 and ipamorelin blend contains at least one ingredient that is prohibited under the WADA Prohibited List. [13]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound the CJC-1295 and ipamorelin blend, with or without a prescription. [11]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [26] [27] [28]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [18] [28] [29]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [22] [30] [31] [32] [33] [34]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [22]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [26]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [18]
  • Pharmacy: Is this made for me on a prescription written in my name? [29]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [18] [28]
  • Prescriber: What is the legal basis for a pharmacy to compound the CJC-1295 and ipamorelin blend? Is it FDA approved or on the 503A bulks list? [11] [22]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [18]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [23]

Compare the ingredients

Blends that share an ingredient

  • Sermorelin and ipamorelin: Sermorelin and ipamorelin pair a formerly approved GHRH fragment with a ghrelin mimetic. The pair is untested, and ipamorelin has no compounding basis.
  • Tesamorelin and ipamorelin: Tesamorelin is FDA approved as Egrifta; ipamorelin has no compounding basis. Mixed together they are untested and cannot be compounded.

Frequently asked questions

What is CJC-1295 and ipamorelin?

It is a pairing of CJC-1295, a long-acting GHRH analog, with ipamorelin, a selective ghrelin receptor agonist, sold to raise growth hormone. Each works on a different release pathway. The pair has never been tested. [2] [3]

Does CJC-1295 with ipamorelin work?

It has not been studied. CJC-1295 raises growth hormone and IGF-1 in small trials, and ipamorelin's one randomized human trial was negative for its surgical use. No study measured muscle, fat, or sleep with either peptide or the pair. [3] [6]

How long does CJC-1295 and ipamorelin take to show results?

There is no evidence-based answer. No study has measured body composition, strength, or sleep outcomes with the pair, and the hormone rises seen in CJC-1295 trials do not show those outcomes. [3] [8]

Is CJC-1295 without DAC the same as CJC-1295?

No. What is sold as CJC-1295 without DAC is modified GRF (1-29), which lacks the drug affinity complex that binds albumin and gives CJC-1295 a half-life of about a week. The published trials tested the version with DAC. [3] [8]

Is CJC-1295 and ipamorelin legal?

Not for human use. Both 503A nominations were withdrawn, neither is on the 503A bulks list, and neither is part of an approved drug, so no pharmacy can lawfully compound them. Research-chemical products sold for human use are unapproved drugs. [10] [11] [15]

What are the side effects of CJC-1295 and ipamorelin?

The pair has no safety study. CJC-1295 trials reported injection site reactions, flushing, and headache, FDA cited increased heart rate and vasodilatory reactions, and reviews list fluid retention, joint pain, appetite changes, and blood glucose problems with growth hormone axis peptides. [3] [8] [10]

Is CJC-1295 and ipamorelin banned in sport?

Yes. Both are named in WADA section S2, and anti-doping laboratories have published methods to identify them in products and urine. [5] [7] [13]

What is the difference between CJC-1295 and ipamorelin?

CJC-1295 mimics GHRH and acts for days after one injection; ipamorelin mimics ghrelin and triggers short growth hormone pulses. CJC-1295 has small human hormone trials, while ipamorelin's growth hormone data come from animals and one small pharmacology study of a single IV infusion in healthy men. [2] [3] [14]

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Bowers CY et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990PubMed 2108187, 1990
  2. [2]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998PubMed 9849822, 1998
  3. [3]Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006PubMed 16352683, 2006
  4. [4]Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010PubMed 20554713, 2010
  5. [5]Henninge J et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal 2010PubMed 21204297, 2010
  6. [6]Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014PubMed 25331030, 2014
  7. [7]Semenistaya E et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin. Drug Test Anal 2015PubMed 25869809, 2015
  8. [8]Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating the GH-IGF-1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026PubMed 42395176, 2026
  9. [9]FDA prescribing information for Egrifta SV (tesamorelin for injection), via DailyMedFDA, 2025
  10. [10]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 30). CJC-1295 and ipamorelin: what is in it and does it work?. https://peptideagent.ai/blends/cjc-1295-ipamorelin
HTML link
<a href="https://peptideagent.ai/blends/cjc-1295-ipamorelin">CJC-1295 and ipamorelin: what is in it and does it work?</a>, PeptideAgent, updated September 30, 2026.